Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Sacubitril/valsartan (Entresto) may help keep atrial fibrillation at bay after catheter ablation. The SUPERIOR trial found that older hypertensive patients on Entresto post-ablation had significantly fewer AFib recurrences compared to those on valsartan alone. Researchers believe the drug's neprilysin inhibition may reduce atrial stretch, inflammation, and fibrosis — going beyond standard blood pressure control.
After catheter ablation for atrial fibrillation (AFib), recurrence remains a real concern — especially in older patients with high blood pressure. The SUPERIOR trial, presented at the American Heart Association Scientific Sessions, suggests that the drug choice after ablation could make a meaningful difference.
The trial enrolled 320 patients aged 55–79 with AFib and hypertension who underwent catheter ablation. Post-procedure, they were randomized to either valsartan or sacubitril/valsartan (Entresto). Over a year of follow-up, those on Entresto had significantly fewer recurrences of atrial tachyarrhythmias compared to the valsartan group.
By the Numbers:
Why it matters: Experts believe Entresto's neprilysin inhibition boosts natriuretic peptides, which may reduce atrial stretch, inflammation, and fibrosis — directly targeting the underlying substrate that drives AFib recurrence. Whether benefits extend beyond one year or apply to broader patient populations remains to be seen.
